

# Mona O Mohsen

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8861504/publications.pdf>

Version: 2024-02-01

40  
papers

1,885  
citations

361413

20  
h-index

330143

37  
g-index

50  
all docs

50  
docs citations

50  
times ranked

2247  
citing authors

#	ARTICLE	IF	CITATIONS
1	Major findings and recent advances in virus-like particle (VLP)-based vaccines. <i>Seminars in Immunology</i> , 2017, 34, 123-132.	5.6	375
2	Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis, therapeutics and vaccines. <i>Annals of Medicine</i> , 2022, 54, 524-540.	3.8	225
3	On Iron Metabolism and Its Regulation. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4591.	4.1	141
4	Harnessing Nanoparticles for Immunomodulation and Vaccines. <i>Vaccines</i> , 2017, 5, 6.	4.4	113
5	Interaction of Viral Capsid-Derived Virus-Like Particles (VLPs) with the Innate Immune System. <i>Vaccines</i> , 2018, 6, 37.	4.4	113
6	Virus-like particles for vaccination against cancer. <i>Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology</i> , 2020, 12, e1579.	6.1	74
7	Delivering adjuvants and antigens in separate nanoparticles eliminates the need of physical linkage for effective vaccination. <i>Journal of Controlled Release</i> , 2017, 251, 92-100.	9.9	69
8	In vitro data suggest that Indian delta variant B.1.617 of SARS-CoV-2 escapes neutralization by both receptor affinity and immune evasion. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 111-117.	5.7	69
9	The 3Ds in virus-like particle based vaccines: Design, Delivery and Dynamics. <i>Immunological Reviews</i> , 2020, 296, 155-168.	6.0	57
10	SARS-CoV-2 structural features may explain limited neutralizing-antibody responses. <i>Npj Vaccines</i> , 2021, 6, 2.	6.0	48
11	Vaccination with nanoparticles combined with micro-adjuvants protects against cancer. , 2019, 7, 114.		41
12	Targeting Mutated Plus Germline Epitopes Confers Pre-clinical Efficacy of an Instantly Formulated Cancer Nano-Vaccine. <i>Frontiers in Immunology</i> , 2019, 10, 1015.	4.8	39
13	Virus-like particles (VLP) in prophylaxis and immunotherapy of allergic diseases. <i>Allergo Journal International</i> , 2018, 27, 245-255.	2.0	38
14	A scalable and highly immunogenic virus-like particle-based vaccine against SARS-CoV-2. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 243-257.	5.7	35
15	Zika Virus-Derived E-DIII Protein Displayed on Immunologically Optimized VLPs Induces Neutralizing Antibodies without Causing Enhancement of Dengue Virus Infection. <i>Vaccines</i> , 2019, 7, 72.	4.4	33
16	Development of a Vaccine against SARS-CoV-2 Based on the Receptor-Binding Domain Displayed on Virus-Like Particles. <i>Vaccines</i> , 2021, 9, 395.	4.4	32
17	New 3-Cyano-2-Substituted Pyridines Induce Apoptosis in MCF 7 Breast Cancer Cells. <i>Molecules</i> , 2016, 21, 230.	3.8	30
18	BNT162b2 mRNA COVID-19 vaccine induces antibodies of broader cross-reactivity than natural infection, but recognition of mutant viruses is up to 10-fold reduced. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 2895-2998.	5.7	29

#	ARTICLE	IF	CITATIONS
19	Virus-Like Particle (VLP) Plus Microcrystalline Tyrosine (MCT) Adjuvants Enhance Vaccine Efficacy Improving T and B Cell Immunogenicity and Protection against <i>Plasmodium berghei/vivax</i> . <i>Vaccines</i> , 2017, 5, 10.	4.4	28
20	The impact of size on particle drainage dynamics and antibody response. <i>Journal of Controlled Release</i> , 2021, 331, 296-308.	9.9	27
21	Molecular definition of severe acute respiratory syndrome coronavirus 2 receptorâ€binding domain mutations: Receptor affinity versus neutralization of receptor interaction. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 143-149.	5.7	26
22	AP205 VLPs Based on Dimerized Capsid Proteins Accommodate RBM Domain of SARS-CoV-2 and Serve as an Attractive Vaccine Candidate. <i>Vaccines</i> , 2021, 9, 403.	4.4	25
23	Vaccination against Allergy: A Paradigm Shift?. <i>Trends in Molecular Medicine</i> , 2020, 26, 357-368.	6.7	24
24	Microcrystalline Tyrosine (MCTÂ®): A Depot Adjuvant in Licensed Allergy Immunotherapy Offers New Opportunities in Malaria. <i>Vaccines</i> , 2017, 5, 32.	4.4	15
25	Bedside formulation of a personalized multi-neoantigen vaccine against mammary carcinoma. , 2022, 10, e002927.		14
26	Intranasal administration of a virus like particlesâ€based vaccine induces neutralizing antibodies against SARSâ€CoVâ€2 and variants of concern. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 2446-2458.	5.7	14
27	Shaping Modern Vaccines: Adjuvant Systems Using MicroCrystalline Tyrosine (MCTÂ®). <i>Frontiers in Immunology</i> , 2020, 11, 594911.	4.8	12
28	Neutralization of MERS coronavirus through a scalable nanoparticle vaccine. <i>Npj Vaccines</i> , 2021, 6, 107.	6.0	12
29	TLR7 Signaling Shapes and Maintains Antibody Diversity Upon Virus-Like Particle Immunization. <i>Frontiers in Immunology</i> , 2021, 12, 827256.	4.8	11
30	Increased Receptor Affinity and Reduced Recognition by Specific Antibodies Contribute to Immune Escape of SARS-CoV-2 Variant Omicron. <i>Vaccines</i> , 2022, 10, 743.	4.4	11
31	Early Transcriptional Signature in Dendritic Cells and the Induction of Protective T Cell Responses Upon Immunization With VLPs Containing TLR Ligandsâ€A Role for CCL2. <i>Frontiers in Immunology</i> , 2019, 10, 1679.	4.8	10
32	A Novel Double Mosaic Virus-like Particle-Based Vaccine against SARS-CoV-2 Incorporates Both Receptor Binding Motif (RBM) and Fusion Domain. <i>Vaccines</i> , 2021, 9, 1287.	4.4	10
33	Culpability, blame, and stigma after pregnancy loss in Qatar. <i>BMC Pregnancy and Childbirth</i> , 2019, 19, 215.	2.4	9
34	Virus-Like Particles Are Efficient Tools for Boosting mRNA-Induced Antibodies. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	8
35	DOPS Adjuvant Confers Enhanced Protection against Malaria for VLP-TRAP Based Vaccines. <i>Diseases (Basel, Switzerland)</i> , 2018, 6, 107.	2.5	7
36	Murine CD8 Tâ€cell functional avidity is stable in vivo but not in vitro: Independence from homologous prime/boost time interval and antigen density. <i>European Journal of Immunology</i> , 2020, 50, 505-514.	2.9	6

#	ARTICLE	IF	CITATIONS
37	Anti-IAPP Monoclonal Antibody Improves Clinical Symptoms in a Mouse Model of Type 2 Diabetes. Vaccines, 2021, 9, 1316.	4.4	6
38	Increased receptor affinity of SARS-CoV-2: a new immune escape mechanism. Npj Vaccines, 2022, 7, .	6.0	6
39	Induction of Broadly Cross-Reactive Antibodies by Displaying Receptor Binding Domains of SARS-CoV-2 on Virus-like Particles. Vaccines, 2022, 10, 307.	4.4	4
40	Cover Image, Volume 12, Issue 1. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 2020, 12, e1610.	6.1	0